Dan Beney Named Bluegrass Vascular Vice President of Sales

Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, today announced Dan Beney has joined the company’s executive team as Vice President of Sales.

In this role, Dan Beney will lead the expansion of the company’s sales efforts to drive the utilization of the Surfacer® Inside-Out® Access Catheter System to facilitate central venous access for patients with venous obstructions.

Mr. Beney has more than 35 years of experience in senior sales leadership positions within the medical device industry. Prior to joining Bluegrass Vascular, Dan served as Vice President of Sales at Avenu Medical (acquired by Medtronic), Vice President of Focal Therapeutics (acquired by Hologic), Vice President of International Sales and Business Development at Cianna Medical (acquired by Merit Medical), Vice President of Sales and Marketing for Intact Medical Corporation (acquired by Medtronic), and as the National Sales Manager for the Breast Care division of Johnson & Johnson (formerly Biopsys Medical). In addition, Dan has also held executive management positions with Conceptus, Neurometrix and Scimed Life Systems. Dan earned his Bachelor of Arts degree in Advertising from Michigan State University.

“It’s exciting to join a team with such innovative, life-saving technology,” Beney said. “Bluegrass Vascular’s commitment to improving the patient outcomes and the work the company has done to date to develop and establish the Surfacer System has created a solid foundation for future growth.”

“Dan is a results-driven leader in the medical device industry who brings extensive experience scaling teams and driving the adoption of innovative technologies,” stated Gabriele Niederauer, Ph.D., CEO and President of Bluegrass Vascular. “His sales leadership, professional relationships with key thought leaders, and his strong background in building top performing sales teams will help to accelerate the company’s growth.”

About the Surfacer® Inside-Out® Access Catheter System: The Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter.

This proprietary Inside-Out approach allows for the placement and maturation of permanent arteriovenous access options that are associated with improved patient outcomes and reduced cost of care for both hospitals and hemodialysis providers.

The Surfacer System has received FDA De Novo device clearance in the US and is CE
marked in Europe. The device is currently distributed in North America and Europe by Merit Medical, a global manufacturer and distributor of medical devices.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”